摘要
目的分析雾化吸入布地奈德治疗慢性阻塞性肺疾病急性加重(AECOPD)合并2型糖尿病(T2DM)患者疗效及对肺通气功能和糖代谢指标的影响。方法选择四川大学华西医院2019年1月至2020年5月诊治的120例AECOPD合并T2DM患者作为对象,根据非随机临床同期对照研究及患者自愿原则分为对照组58例和观察组62例,其中对照组给予低剂量布地奈德治疗,观察组给予高剂量布地奈德治疗。比较两组患者治疗前后肺通气功能、糖代谢指标和炎性因子水平变化,并评估疗效和安全性。结果两组患者治疗有效率比较无显著差异(P>0.05);与治疗前比,两组患者治疗后肺通气功能指标均显著升高,但观察组较对照组升高更为显著(P<0.05);两组患者之间及其治疗前后糖代谢指标均无显著差异(P>0.05);与治疗前比,两组患者治疗后炎症因子水平均显著降低,但观察组较对照组降低更为显著(P<0.05);两组不良反应发生率比较无统计学意义(P>0.05)。结论布地奈德雾化吸入治疗AECOPD合并T2DM安全有效,对糖代谢指标无明显影响,但高剂量的布地奈德对于患者肺通气功能和炎症水平改善效果更好。
Objective To study the therapeutic effects of aerosol inhalation of budesonide on acute exacerbation of chronic obstructive pulmonary disease(AECOPD)with type 2 diabetes mellitus(T2DM)and the influence on pulmonary ventilation function and glucose metabolism indicators.Methods Between January 2019 and May 2020,120 patients with AECOPD and T2DM were selected as the subjects.According to the non-randomized clinical concurrent controlled study and patient voluntary principle,they were divided into control group 58 cases and observation group 62 cases.Control Group was treated with low-dose budesonide,while observation group was treated with high-dose budesonide.Changes in pulmonary ventilation function,glucose metabolism indicators and inflammatory factors before and after treatment were compared between the two groups.The efficacy and safety were evaluated.Results There was no significant difference in the response rate between the two groups(P>0.05).After treatment,the pulmonary ventilation function indexes significantly increased,and the increases were greater in observation group than in control group(P<0.05).No significant differences were observed in glucose metabolism indexes between the two groups or in the same group before and after treatment(P>0.05).After treatment,the levels of inflammatory factors decreased significantly,and the decreases were greater in observation group than in control group(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Aerosol inhalation of budesonide is safe and effective in the treatment of AECOPD with T2DM,without significant effect on glucose metabolism.However,high-dose budesonide can better improve pulmonary ventilation and relieve inflammation.
作者
刘璐
赖倩
Liu Lu;Lai Qian(Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu 610000, China)
出处
《中华肺部疾病杂志（电子版）》
2021年第4期427-430,共4页
Chinese Journal of Lung Diseases(Electronic Edition)
关键词
布地奈德
肺疾病
慢性阻塞性
2型糖尿病
肺通气功能
糖代谢
Budesonide
Chronic obstructive pulmonary disease
Type 2 diabetes mellitus
Pulmonary ventilation function
Glucose metabolism
